Dr. Ho and colleagues were the first to demonstrate the translational potential of nanodiamonds as chemotherapeutic delivery agents, specifically towards the treatment of drug-resistant cancers in vivo.
His team and colleagues pioneered the field of Augmented AI (CURATE.AI), which mediates model-free and mechanism-independent N-of-1 combination therapy and rapidly accelerated and globally optimized drug development.
[5][6] This AI platform has realized best-in-class medicines for population-wide administration, as well as the unprecedented ability to actionably personalize treatment for the entire duration of care on a patient-specific basis.
[7] Dr. Ho's extensive research achievements have garnered news coverage in The Economist,[8] Forbes,[9] Nature, CNN,[10] NPR, as well as The Washington Post.
He also served as the President of the Board of Directors of the Society for Laboratory Automation and Screening which is a 20,000+ member drug development and life sciences technology organization.